Analysis of the Cochrane Review: Pregabalin for Pain in Fibromyalgia in Adults. Cochrane Database Syst Rev. 2016;9:CD011790 and 2016;4:CD009002
Autor(a) principal: | |
---|---|
Data de Publicação: | 2018 |
Outros Autores: | , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10433 |
Resumo: | Fibromyalgia can be clinically defined by widespread pain lasting for longer than 3 months with tenderness on palpation in 11 or more of 18 specified tender points. Many people with fibromyalgia are significantly disabled, and experience moderate to severe pain for many years, for which conventional analgesics are usually not effective. For these patients treatment options generally include antidepressants like tricyclic agents, serotonin and noradrenaline reuptake inhibitors, or anticonvulsants like pregabalin or gabapentin. Pregabalin is a drug licensed for the treatment of fibromyalgia in the United States of America, with a mechanism of action similar to gabapentin. This mode of action confers antiepileptic, analgesic, and anxiolytic effects. This Cochrane systematic review included 8 randomized, placebo-controlled trials with low risk of bias, which studied the effect of a daily dose of pregabalin for the treatment of moderate to severe pain in adult patients suffering from fibromyalgia. Of the main results of this systematic review we highlight the major effect that a daily dose of 300 to 600 mg of pregabalin had in the reduction of pain intensity over a follow-up period of 12 to 26 weeks, with tolerable adverse effects, for a minority of people with moderate to severe pain due to fibromyalgia. This paper aims to summarize and discuss the main results and conclusions of this systematic review, as well as its implications for the daily clinical practice. |
id |
RCAP_3b040cb1a8d069e51396ebfacbe4dd61 |
---|---|
oai_identifier_str |
oai:ojs.www.actamedicaportuguesa.com:article/10433 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Analysis of the Cochrane Review: Pregabalin for Pain in Fibromyalgia in Adults. Cochrane Database Syst Rev. 2016;9:CD011790 and 2016;4:CD009002Análise da Revisão Cochrane: Pregabalina no Tratamento da Dor Crónica Moderada a Grave em Adultos com Fibromialgia. Cochrane Database Syst Rev. 2016;9:CD011790 e 2016;4:CD009002Chronic PainFibromyalgiaPregabalinRandomized Controlled TrialsSystematic ReviewDor CrónicaEnsaios Clínicos AleatorizadosFibromialgiaPregabalinaRevisão SistemáticaFibromyalgia can be clinically defined by widespread pain lasting for longer than 3 months with tenderness on palpation in 11 or more of 18 specified tender points. Many people with fibromyalgia are significantly disabled, and experience moderate to severe pain for many years, for which conventional analgesics are usually not effective. For these patients treatment options generally include antidepressants like tricyclic agents, serotonin and noradrenaline reuptake inhibitors, or anticonvulsants like pregabalin or gabapentin. Pregabalin is a drug licensed for the treatment of fibromyalgia in the United States of America, with a mechanism of action similar to gabapentin. This mode of action confers antiepileptic, analgesic, and anxiolytic effects. This Cochrane systematic review included 8 randomized, placebo-controlled trials with low risk of bias, which studied the effect of a daily dose of pregabalin for the treatment of moderate to severe pain in adult patients suffering from fibromyalgia. Of the main results of this systematic review we highlight the major effect that a daily dose of 300 to 600 mg of pregabalin had in the reduction of pain intensity over a follow-up period of 12 to 26 weeks, with tolerable adverse effects, for a minority of people with moderate to severe pain due to fibromyalgia. This paper aims to summarize and discuss the main results and conclusions of this systematic review, as well as its implications for the daily clinical practice.A fibromialgia é uma doença caracterizada por dor generalizada, com mais de três meses de duração, com dor à palpação em pelo menos 11 de 18 pontos anatomicamente definidos. Um elevado número de doentes com fibromialgia sofre de dor moderada a grave durante vários anos, para a qual os analgésicos convencionais se mostraram ineficazes, de tal forma que foram substituídos por antidepressivos tricíclicos, inibidores seletivos da recaptação da serotonina e noradrenalina e anticonvulsivantes, como a pregabalina e a gabapentina. A pregabalina é um fármaco anti-epilético aprovado para o tratamento da fibromialgia nos Estados Unidos da América, cujo mecanismo de ação se assemelha ao da gabapentina, com efeitos anticonvulsivante, analgésico e ansiolítico. Nesta revisão sistemática Cochrane os autores incluíram um total de oito ensaios clínicos aleatorizados, controlados por placebo, com baixo risco global de viés, que estudaram o efeito da administração de uma dose diária de pregabalina no tratamento da dor crónica moderada a grave, em doentes adultos com fibromialgia. Dos principais resultados desta revisão sistemática destacam-se o efeito substancial que uma dose diária de 300 a 600 mg de pregabalina teve na diminuição da intensidade da dor moderada a grave, numa minoria dos doentes adultos com fibromialgia, durante um período de follow-up de 12 a 26 semanas, bem como a elevada incidência de eventos adversos associados ao tratamento, a maioria dos quais bem tolerados. Neste artigo sumarizam-se e discutem-se os principais resultados e conclusões desta revisão sistemática, bem como as suas implicações para a prática clínica diária. Ordem dos Médicos2018-08-31info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfapplication/pdfapplication/pdfhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10433oai:ojs.www.actamedicaportuguesa.com:article/10433Acta Médica Portuguesa; Vol. 31 No. 7-8 (2018): July-August; 376-381Acta Médica Portuguesa; Vol. 31 N.º 7-8 (2018): Julho-Agosto; 376-3811646-07580870-399Xreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10433https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10433/5462https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10433/10177https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10433/10494Direitos de Autor (c) 2018 Acta Médica Portuguesainfo:eu-repo/semantics/openAccessFerreira-Dos-Santos, GuilhermeSousa, David CordeiroCosta, JoãoVaz-Carneiro, António2022-12-20T11:05:59Zoai:ojs.www.actamedicaportuguesa.com:article/10433Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T16:19:53.217051Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Analysis of the Cochrane Review: Pregabalin for Pain in Fibromyalgia in Adults. Cochrane Database Syst Rev. 2016;9:CD011790 and 2016;4:CD009002 Análise da Revisão Cochrane: Pregabalina no Tratamento da Dor Crónica Moderada a Grave em Adultos com Fibromialgia. Cochrane Database Syst Rev. 2016;9:CD011790 e 2016;4:CD009002 |
title |
Analysis of the Cochrane Review: Pregabalin for Pain in Fibromyalgia in Adults. Cochrane Database Syst Rev. 2016;9:CD011790 and 2016;4:CD009002 |
spellingShingle |
Analysis of the Cochrane Review: Pregabalin for Pain in Fibromyalgia in Adults. Cochrane Database Syst Rev. 2016;9:CD011790 and 2016;4:CD009002 Ferreira-Dos-Santos, Guilherme Chronic Pain Fibromyalgia Pregabalin Randomized Controlled Trials Systematic Review Dor Crónica Ensaios Clínicos Aleatorizados Fibromialgia Pregabalina Revisão Sistemática |
title_short |
Analysis of the Cochrane Review: Pregabalin for Pain in Fibromyalgia in Adults. Cochrane Database Syst Rev. 2016;9:CD011790 and 2016;4:CD009002 |
title_full |
Analysis of the Cochrane Review: Pregabalin for Pain in Fibromyalgia in Adults. Cochrane Database Syst Rev. 2016;9:CD011790 and 2016;4:CD009002 |
title_fullStr |
Analysis of the Cochrane Review: Pregabalin for Pain in Fibromyalgia in Adults. Cochrane Database Syst Rev. 2016;9:CD011790 and 2016;4:CD009002 |
title_full_unstemmed |
Analysis of the Cochrane Review: Pregabalin for Pain in Fibromyalgia in Adults. Cochrane Database Syst Rev. 2016;9:CD011790 and 2016;4:CD009002 |
title_sort |
Analysis of the Cochrane Review: Pregabalin for Pain in Fibromyalgia in Adults. Cochrane Database Syst Rev. 2016;9:CD011790 and 2016;4:CD009002 |
author |
Ferreira-Dos-Santos, Guilherme |
author_facet |
Ferreira-Dos-Santos, Guilherme Sousa, David Cordeiro Costa, João Vaz-Carneiro, António |
author_role |
author |
author2 |
Sousa, David Cordeiro Costa, João Vaz-Carneiro, António |
author2_role |
author author author |
dc.contributor.author.fl_str_mv |
Ferreira-Dos-Santos, Guilherme Sousa, David Cordeiro Costa, João Vaz-Carneiro, António |
dc.subject.por.fl_str_mv |
Chronic Pain Fibromyalgia Pregabalin Randomized Controlled Trials Systematic Review Dor Crónica Ensaios Clínicos Aleatorizados Fibromialgia Pregabalina Revisão Sistemática |
topic |
Chronic Pain Fibromyalgia Pregabalin Randomized Controlled Trials Systematic Review Dor Crónica Ensaios Clínicos Aleatorizados Fibromialgia Pregabalina Revisão Sistemática |
description |
Fibromyalgia can be clinically defined by widespread pain lasting for longer than 3 months with tenderness on palpation in 11 or more of 18 specified tender points. Many people with fibromyalgia are significantly disabled, and experience moderate to severe pain for many years, for which conventional analgesics are usually not effective. For these patients treatment options generally include antidepressants like tricyclic agents, serotonin and noradrenaline reuptake inhibitors, or anticonvulsants like pregabalin or gabapentin. Pregabalin is a drug licensed for the treatment of fibromyalgia in the United States of America, with a mechanism of action similar to gabapentin. This mode of action confers antiepileptic, analgesic, and anxiolytic effects. This Cochrane systematic review included 8 randomized, placebo-controlled trials with low risk of bias, which studied the effect of a daily dose of pregabalin for the treatment of moderate to severe pain in adult patients suffering from fibromyalgia. Of the main results of this systematic review we highlight the major effect that a daily dose of 300 to 600 mg of pregabalin had in the reduction of pain intensity over a follow-up period of 12 to 26 weeks, with tolerable adverse effects, for a minority of people with moderate to severe pain due to fibromyalgia. This paper aims to summarize and discuss the main results and conclusions of this systematic review, as well as its implications for the daily clinical practice. |
publishDate |
2018 |
dc.date.none.fl_str_mv |
2018-08-31 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10433 oai:ojs.www.actamedicaportuguesa.com:article/10433 |
url |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10433 |
identifier_str_mv |
oai:ojs.www.actamedicaportuguesa.com:article/10433 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10433 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10433/5462 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10433/10177 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10433/10494 |
dc.rights.driver.fl_str_mv |
Direitos de Autor (c) 2018 Acta Médica Portuguesa info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Direitos de Autor (c) 2018 Acta Médica Portuguesa |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Ordem dos Médicos |
publisher.none.fl_str_mv |
Ordem dos Médicos |
dc.source.none.fl_str_mv |
Acta Médica Portuguesa; Vol. 31 No. 7-8 (2018): July-August; 376-381 Acta Médica Portuguesa; Vol. 31 N.º 7-8 (2018): Julho-Agosto; 376-381 1646-0758 0870-399X reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1817550466019491840 |